RecruitingPhase 3NCT03150693
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Sponsor: Alliance for Clinical Trials in Oncology
Ashland, WI · Hayward, WI · +452 more sites
Leukemia clinical trials in Milwaukee, WI
29 recruiting leukemia studies with a site in Milwaukee, WI.
RecruitingPhase 2NCT06317662
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Sponsor: National Cancer Institute (NCI)
Green Bay, WI · Milwaukee, WI · +113 more sites
RecruitingPhase 2NCT05554393
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Appleton, WI · Ashland, WI · +172 more sites
RecruitingPhase 2NCT06317649
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Appleton, WI · Ashland, WI · Green Bay, WI · +222 more sites
RecruitingPhase 1 / Phase 2NCT06137118
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Sponsor: AstraZeneca
Milwaukee, WI · +11 more sites
RecruitingPhase 2NCT06672146
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Ashland, WI · Green Bay, WI · +132 more sites
RecruitingPhase 3NCT07007312
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Sponsor: Kura Oncology, Inc.
Madison, WI · Milwaukee, WI · +42 more sites
RecruitingPhase 2NCT06707493
Ivosidenib as Post-HSCT Maintenance for AML
Sponsor: Massachusetts General Hospital
Milwaukee, WI · +6 more sites
RecruitingPhase 1NCT03802695
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Sponsor: Orca Biosystems, Inc.
Milwaukee, WI · +11 more sites
RecruitingPhase 3NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Sponsor: BeOne Medicines
Milwaukee, WI · +21 more sites
RecruitingPhase 3NCT04293562
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Sponsor: Children's Oncology Group
Green Bay, WI · Madison, WI · Marshfield, WI · +183 more sites
RecruitingPhase 2NCT07221500
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Sponsor: Nurix Therapeutics, Inc.
Milwaukee, WI · +26 more sites
RecruitingPhase 1NCT04972942
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Sponsor: New York Medical College
Milwaukee, WI · +15 more sites
RecruitingPhase 1NCT03666000
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sponsor: Imugene Limited
Milwaukee, WI · +9 more sites
RecruitingPhase not listedNCT05702645
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
Sponsor: Children's Oncology Group
Madison, WI · Marshfield, WI · Milwaukee, WI · +69 more sites
RecruitingPhase 1NCT06001788
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: Kura Oncology, Inc.
Milwaukee, WI · +37 more sites
RecruitingPhase 1NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Sponsor: Nurix Therapeutics, Inc.
Milwaukee, WI · +17 more sites
RecruitingPhase not listedNCT05865301
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Sponsor: Stanford University
Milwaukee, WI · +21 more sites
RecruitingPhase not listedNCT01790152
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Sponsor: Children's Oncology Group
Milwaukee, WI · +68 more sites
RecruitingPhase 1NCT05544968
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Sponsor: Medical College of Wisconsin
Milwaukee, WI
RecruitingPhase 2NCT07218510
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Sponsor: City of Hope Medical Center
Milwaukee, WI · +6 more sites
RecruitingPhase 4NCT06876649
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Sponsor: Eli Lilly and Company
Milwaukee, WI · +19 more sites
RecruitingPhase 1NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Sponsor: Carna Biosciences, Inc.
Milwaukee, WI · +12 more sites
RecruitingPhase not listedNCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Sponsor: Medical College of Wisconsin
Milwaukee, WI
RecruitingPhase not listedNCT06788639
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Milwaukee, WI
RecruitingPhase not listedNCT04014374
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Sponsor: Kyowa Kirin, Inc.
Milwaukee, WI
RecruitingPhase 2NCT04746209
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Sponsor: Medical College of Wisconsin
Milwaukee, WI
Not yet recruitingNot applicableNCT07809984
Prevention of Oral Mucositis in Adults in With Hematologic Malignancy
Sponsor: Wake Forest University Health Sciences
Milwaukee, WI · +2 more sites
Not yet recruitingPhase 2NCT07690891
Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
Sponsor: Medical College of Wisconsin
Milwaukee, WI
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.